3 papers in the library · 2,647 citations · publishing 2016-2021
J Psychopharmacol February 18, 2021 Ben Sessa, Laurie Higbed, Steve O’Brien et al. 123 citations
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder.
Psychopharmacology (Berl) November 8, 2017 R. L. Carhart-Harris, Mark Bolstridge, C. M. J. Day et al. 978 citations
RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major...
Lancet Psychiatry May 17, 2016 Robin Carhart-Harris, Mark Bolstridge, James Rucker et al. 1,546 citations
BACKGROUND: Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy...